CRCurzio Rüegg

Curzio Rüegg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Curzio Rüegg has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Olivier Dormond

    Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), CH-1011 Lausanne, Switzerland

    5 shared publications
  • Agnese Mariotti

    Lausanne, Switzerland

    3 shared publications
  • Roger Stupp

    Centre Pluridisciplianire d'Oncologie (CePO), Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

    3 shared publications
  • Doris Gundersen

    Laboratory of the Centre Pluridisciplinaire d'Oncologie at the Swiss Institute for Experimental Cancer Research, Epalinges, Switzerland

    2 shared publications
  • Khalil Zaman

    Centre Pluridisciplianire d'Oncologie (CePO), Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

    2 shared publications
  • Patricia Werffeli

    Centre Pluridisciplianire d'Oncologie (CePO), Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland

    2 shared publications

Latest Publications

  • Monitoring multiple angiogenesis‐related molecules in the blood of cancer patients shows a correlation between VEGF‐A and MMP‐9 levels before treatment and divergent changes after surgical vs. conservative therapy

    by Khalil Zaman, Robert Driscoll, Diane Hahn, Patricia Werffeli, Simon L. Goodman, Jean Bauer, Serge Leyvraz, Ferdy Lejeune, Roger Stupp, Curzio Rüegg

    Anti‐angiogenic therapies are currently in cancer clinical trials, but to date there are no established tests for evaluating the angiogenic status of a patient. We measured 11 circulating angiogenesis‐associated molecules in cancer patients before and after local treatment. The purpose of our study was to screen for possible relationships among the different molecules and between individual molecules and tumor burden. We measured VEGF‐A, PlGF, SCF, MMP‐9, EDB+‐fibronectin, sVEGFR‐2, sVEGFR‐1, sαVβ3, sTie‐2, IL‐8 and CRP in the blood of 22 healthy volunteers, 17 early breast, 17 early colorectal, and 8 advanced sarcoma/melanoma cancer patients. Breast cancer patients had elevated levels of VEGF‐A and sTie‐2, colorectal cancer patients of VEGF‐A, MMP‐9, sTie‐2, IL‐8 and CRP, and melanoma/sarcoma patients of sVEGFR‐1. sαVβ3 was decreased in colorectal cancer patients. A correlation between VEGF‐A and MMP‐9 was found. After tumor removal, MMP‐9 and sαVβ3 significantly decreased in breast and CRP in colorectal cancer, whereas sVEGFR‐1 increased in colorectal cancer patients. In sarcoma/melanoma patients treated regionally with TNF and chemotherapy we observed a rise in VEGF‐A, SCF, VEGFR‐2, MMP‐9, Tie‐2 and CRP, a correlation between CRP and IL‐8, and a decreased in sVEGFR‐1 levels. In conclusion, among all factors measured, only VEGF‐A and MMP‐9 consistently correlated to each other, elevated CRP levels were associated with tumor burden, whereas sVEGF‐R1 increased after tumor removal in colorectal cancer. Treatment with chemotherapy and TNF induced changes consistent with an angiogenic switch. These results warrant a prospective study to compare the effect of surgical tumor removal vs. chemotherapy on some of these markers and to evaluate their prognostic/predictive value.


  • Manganese-induced integrin affinity maturation promotes recruitment of αVβ3 integrin to focal adhesions in endothelial cells: evidence for a role of phosphatidylinositol 3-kinase and Src

    by Olivier Dormond, Lionel Ponsonnet, Meriem Hasmim, Alessandro Foletti, Curzio Rüegg

    Integrin activity is controlled by changes in affinity (i.e. ligand binding) and avidity (i.e. receptor clustering). Little is known, however, about the effect of affinity maturation on integrin avidity and on the associated signaling pathways. To study the effect of affinity maturation on integrin avidity, we stimulated human umbilical vein endothelial cells (HUVEC) with MnCl2 to increase integrin affinity and monitored clustering of β1 and β3 integrins. In unstimulated HUVEC, β1 integrins were present in fibrillar adhesions, while αVβ3 was detected in peripheral focal adhesions. Clustered β1 and β3 integrins expressed high affinity/ligand-induced binding site (LIBS) epitopes. MnCl2-stimulation promoted focal adhesion and actin stress fiber formation at the basal surface of the cells, and strongly enhanced mAb LM609 staining and expression of β3 high affinity/LIBS epitopes at focal adhesions. MnCl2-induced αVβ3 clustering was blocked by a soluble RGD peptide, by wortmannin and LY294002, two parmacological inhibitors of phosphatidylinositol 3-kinase (PI 3-K), and by over-expressing a dominant negative PI 3-K mutant protein. Conversely, over-expression of active PI 3-K and pharmacological inhibiton of Src with PP2 and CGP77675, enhanced basal and manganese-induced αVβ3 clustering. Transient increased phosphorylation of protein kinase B/Akt, a direct target of PI 3K, occurred upon manganese stimulation. MnCl2 did not alter β1 integrin distribution or β1 high-affinity/LIBS epitope expression. Based on these results, we conclude that MnCl2-induced αVβ3 integrin affinity maturation stimulates focal adhesion and actin stress fiber formation, and promotes recruitment of high affinity αVβ3 to focal adhesions. Affinity-modulated αVβ3 clustering requires PI3-K signaling and is negatively regulate by Src.


  • The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials

    by Curzio Ruegg, Jean-Yves Meuwly, Robert Driscoll, Patricia Werffeli, Khalil Zaman, Roger Stupp

    Inhibition of tumor angiogenesis suppresses tumor growth and metastatic spreading in many experimental models, suggesting that anti-angiogenic drugs may be used to treat human cancer. During the past decade more than eighty molecules that showed anti-angiogenic activity in preclinical studies were tested in clinical cancer trials, but most of them failed to demonstrate any measurable anti-tumor activity and none have been approved for clinical use. Recent results stemming from trials with anti-VEGF antibodies, used alone or in combination with chemotherapy, suggest that systemic anti-angiogenic therapy may indeed have a measurable impact on cancer progression and patient survival. From the clinical studies it became nevertheless clear that the classical endpoints used in anti-cancer trials do not bring sufficient discriminative power to monitor the effects of anti-angiogenic drugs. It is therefore necessary to identify and validate molecular, cellular and functional surrogate markers of angiogenesis to monitor activity and efficacy of anti-angiogenic drugs in patients. Availability of such markers will be instrumental to re-evaluate the role of tumor angiogenesis in human cancer, to identify new molecular targets and drugs, and to improve planning, monitoring and interpretation of future studies. Future anti-angiogenesis trials integrating biological endpoints and surrogate markers or angiogenesis will require close collaboration between clinical investigators and laboratory-based researchers. Here we review and discuss critical issues and emerging paradigms relevant to tumor angiogenesis and anti-angiogenic drugs and to the monitoring of tumor angiogenesis and anti-angiogenic effects in patients.


  • Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis

    by C. Rüegg, A. Mariotti

    New blood vessel formation, a process referred to as angiogenesis, is essential for embryonic development and for many physiological and pathological processes during postnatal life, including cancer progression. Endothelial cell adhesion molecules of the integrin family have emerged as critical mediators and regulators of angiogenesis and vascular homeostasis. Integrins provide the physical interaction with the extracellular matrix necessary for cell adhesion, migration and positioning, and induction of signaling events essential for cell survival, proliferation and differentiation. Antagonists of integrin αVβ3 suppress angiogenesis in many experimental models and are currently tested in clinical trials for their therapeutic efficacy against angiogenesis-dependent diseases, including cancer. Furthermore, interfering with signaling pathways downstream of integrins results in suppression of angiogenesis and may have relevant therapeutic implications. In this article we review the role of integrins in endothelial cell function and angiogenesis. In the light of recent advances in the field, we will discuss their relevance as a therapeutic target to suppress tumor angiogenesis.


  • Non steroidal anti‐inflammatory drugs and COX‐2 inhibitors as anti‐cancer therapeutics: hypes, hopes and reality

    by Curzio Rüegg, Jelena Zaric, Roger Stupp

    Non‐steroidal anti‐inflammatory drugs (NSAIDs) and specific inhibitors of cyclooxygenase (COX)‐2, are therapeutic groups widely used for the treatment of pain, inflammation and fever. There is growing experimental and clinical evidence indicating NSAIDs and COX‐2 inhibitors also have anti‐cancer activity. Epidemiological studies have shown that regular use of Aspirin and other NSAIDs reduces the risk of developing cancer, in particular of the colon. Molecular pathology studies have revealed that COX‐2 is expressed by cancer cells and cells of the tumor stroma during tumor progression and in response to chemotherapy or radiotherapy. Experimental studies have demonstrated that COX‐2 over expression promotes tumorigenesis, and that NSAIDs and COX‐2 inhibitors suppress tumorigenesis and tumor progression. Clinical trials have shown that NSAIDs and COX‐2 inhibitors suppress colon polyp formation and malignant progression in patients with familial adenomatous polyposis (FAP) syndrome. Recent advances in the understanding of the cellular and molecular mechanisms of the anti‐cancer effects of NSAIDs and COX‐2 inhibitors have demonstrated that these drugs target both tumor cells and the tumor vasculature. The therapeutic benefits of COX‐2 inhibitors in the treatment of human cancer in combination with chemotherapy or radiotherapy are currently being tested in clinical trials. In this article we will review recent advances in the understanding of the anti‐tumor mechanisms of these drugs and discuss their potential application in clinical oncology.


  • Suppression of Tumor Angiogenesis Through the Inhibition of Integrin Function and Signaling in Endothelial Cells: Which Side to Target?

    by C. Rüegg, O. Dormond, A. Foletti

    Tumor angiogenesis is an essential step in tumor progression and metastasis formation. Suppression of tumor angiogenesis results in the inhibition of tumor growth. Recent evidence indicates that vascular integrins, in particular f V g 3, are important regulators of angiogenesis, including tumor angiogenesis. Integrin f V g 3 antagonists, such as blocking antibodies or peptides, suppress tumor angiogenesis and tumor progression in many preclinical tumor models. The potential therapeutic efficacy of extracellular integrin antagonists in human cancer is currently being tested in clinical trials. Selective disruption of the tumor vasculature by high doses of tumor necrosis factor (TNF) and interferon gamma (IFN- n ), and the antiangiogenic activity of nonsteroidal anti-inflammatory drugs are associated with the suppression of integrin f V g 3 function and signaling in endothelial cells. Furthermore, expression of isolated integrin cytoplasmic domains disrupts integrin-dependent adhesion, resulting in endothelial cell detachment and apoptosis. These results confirm the critical role of vascular integrins in promoting endothelial cell survival and angiogenesis and suggest that intracellular targeting of integrin function and signaling may be an alternative strategy to extracellular integrin antagonists for the therapeutic inhibition of tumor angiogenesis.


  • Open Access

    Suppression of Tumor Angiogenesis by Nonsteroidal Anti-Inflammatory Drugs: A New Function for Old Drugs

    by Curzio Raegg, Olivier Dormond

    There is solid epidemiological evidence demonstrating that the regular use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing colorectal cancer, and to a lesser extent gastric and esophageal cancers[1]. Importantly, NSAIDs suppress colon polyp formation and progression in patients diagnosed with familial adenomatous polyposis coli (APC)[2]. In many animal studies, NSAIDs have been shown to prevent tumor formation and slow tumor progression, thus confirming and extending the clinical observations[3,4,5]. Recent findings have demonstrated that NSAIDs inhibit angiogenesis, suggesting that the tumor suppressive activity of these drugs may be due, at least in part, to their ability to inhibit tumor angiogenesis[6]. The study of the mechanism by which NSAIDs suppress tumor angiogenesis, is matter of intense research.


  • Tenascin-C inhibits β1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1 – 5 repeats to fibronectin

    by Dan Hauzenberger, Philippe Olivier, Doris Gundersen, Curzio Rüegg

    The extracellular matrix consists of different proteins interacting to form a meshwork-like structure. T lymphocyte adhesion to individual matrix proteins is mainly regulated at the adhesion receptor level, but it is conceivable that the composition of the matrix itself may affect T lymphocyte adhesion to individual proteins. We have addressed the latter point by studying the effect of the matrix protein tenascin-C (TN-C) on T lymphocyte adhesion to fibronectin. Here we report that TN-C inhibits adhesion of T lymphocytes and MOLT-4 lymphoma cells to fibronectin. We demonstrate that a TNC fragment consisting of fibronectin type III repeats 1 – 5 (TNfnIII 1 – 5) but not TNfnIII A – D and TNfnIII 6 – 8 inhibited α5β1 and α4β1 integrin-mediated T lymphocyte and MOLT-4 adhesion to fibronectin. At concentrations that did not inhibit adhesion, TNfnIII 1 – 5 still prevented MOLT-4 cells from spreading on fibronectin. Preincubation and co-immobilization of TNfnIII 1 –5 with fibronectin was more effective in inhibiting MOLT-4 adhesion to fibronectin than soluble TNfnIII 1 – 5 present during the adhesion test. Using an enzyme-linked immunosorbent assay we could demonstrate binding of TNfnIII 1 – 5 to fibronectin and fibronectin fragments. Taken together, these data demonstrate that the TNfnIII 1 – 5 domain is implicated in the inhibition of T lymphocyte adhesion to fibronectin caused by TN-C, and indicate that this effect involves the binding of TN-C repeats TNfnIII 1 – 5 to fibronectin.